C WorldWide Group’s NovoCure NVCR Stock Holding History

C WorldWide Group’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10.6M	Hold	971,784	–	–	0.23%	52
2025 Q4	$12.6M	Hold	971,784	–	–	0.22%	53
2025 Q3	$12.6M	Buy	971,784 +350,000	+56%	+$4.68M	0.19%	54
2025 Q2	$11.1M	Hold	621,784	–	–	0.15%	61
2025 Q1	$11.1M	Hold	621,784	–	–	0.14%	59
2024 Q4	$18.5M	Buy	621,784 +100,000	+19%	+$2.12M	0.23%	39
2024 Q3	$8.15M	Hold	521,784	–	–	0.08%	68
2024 Q2	$8.94M	Hold	521,784	–	–	0.1%	66
2024 Q1	$8.15M	Hold	521,784	–	–	0.09%	65
2023 Q4	$7.79M	Buy	521,784 +300,000	+135%	+$4.01M	0.1%	62
2023 Q3	$3.58M	Hold	221,784	–	–	0.05%	65
2023 Q2	$9.2M	Hold	221,784	–	–	0.12%	60
2023 Q1	$13.3M	Sell	221,784 -75,000	-25%	-$5.99M	0.18%	54
2022 Q4	$21.8M	Hold	296,784	–	–	0.29%	31
2022 Q3	$22.6M	Hold	296,784	–	–	0.31%	29
2022 Q2	$20.6M	Hold	296,784	–	–	0.26%	29
2022 Q1	$24.6M	Buy	296,784 +55,000	+23%	+$4.05M	0.27%	28
2021 Q4	$18.2M	Buy	241,784 +130,000	+116%	+$13M	0.17%	35
2021 Q3	$13M	Hold	111,784	–	–	0.13%	41
2021 Q2	$24.8M	Sell	111,784 -15,000	-12%	-$2.92M	0.26%	28
2021 Q1	$16.8M	Sell	126,784 -35,000	-22%	-$5.54M	0.16%	45
2020 Q4	$28M	Sell	161,784 -80,000	-33%	-$10.9M	0.28%	32
2020 Q3	$26.9M	Sell	241,784 -100,000	-29%	-$8M	0.3%	30
2020 Q2	$20.3M	Buy	341,784 +175,000	+105%	+$11.5M	0.24%	35
2020 Q1	$11.2M	Hold	166,784	–	–	0.16%	43
2019 Q4	$14.1M	Hold	166,784	–	–	0.17%	41
2019 Q3	$12.5M	Sell	166,784 -41,275	-20%	-$3.3M	0.16%	40
2019 Q2	$13.2M	Buy	208,059 +100,000	+93%	+$5.07M	0.16%	45
2019 Q1	$5.21M	Sell	108,059 -33,035	-23%	-$1.59M	0.07%	54
2018 Q4	$4.72M	Sell	141,094 -23,859	-14%	-$872K	0.07%	50
2018 Q3	$8.64M	Sell	164,953 -48,200	-23%	-$1.92M	0.11%	45
2018 Q2	$6.67M	Buy	213,153 +44,832	+27%	+$1.25M	0.09%	53
2018 Q1	$3.67M	Sell	168,321 -22,479	-12%	-$483K	0.06%	62
2017 Q4	$3.85M	Sell	190,800 -39,700	-17%	-$764K	0.06%	66
2017 Q3	$4.58M	Sell	230,500 -43,100	-16%	-$847K	0.07%	66
2017 Q2	$4.73M	Buy	+273,600	New	+$3.53M	0.07%	63

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

C WorldWide Group's NVCR Position: Q1 2026 in Review

C WorldWide Group held its NovoCure (NVCR) position steady in Q1 2026 at 971,784 shares worth $10.6M. The position accounts for 0.23% of the portfolio, ranked #52.

C WorldWide Group first reported a position in NVCR in Q2 2017 and has held it in 36 quarters since. The position peaked at $28M in Q4 2020. 223 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

C WorldWide Group held 971,784 shares of NovoCure worth $10.6M as of Q1 2026.
C WorldWide Group left its NovoCure share count unchanged in Q1 2026.
NovoCure made up 0.23% of C WorldWide Group's portfolio in Q1 2026, its #52 holding.
C WorldWide Group first reported a position in NovoCure in Q2 2017 and has held it in 36 quarters since.
C WorldWide Group's NovoCure position peaked at $28M in Q4 2020.
223 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on C WorldWide Group's 13F filing for Q1 2026, filed 6 May 2026.